Therapeutic Response

TP53 deletion status confers therapeutic sensitivity to Acalabrutinib in patients with Chronic Lymphocytic Leukemia.

Statements

Source and description

Acalabrutinib (Tablets) Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved acalabrutinib (tablets) for reimbursement as a monotherapy treatment option for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation who are unsuitable for chemoimmunotherapy.